Breast Cancer:

Most Breast Cancers fall into four groups.

Treatment options (Chemotheraepy, Hormone therapy, Immunotherapy, Target therapy) will be based on these groups.

• Group 1: - Luminal A – 40% of breast cancer: ER+VE, PR+VE, HER2-VE, LOW Ki67: (likely to benefit from hormone therapy and may also benefit from chemotherapy)
• Group 2: - Luminal B (TRIPLE POSITIVE) – 20% of breast cancer: ER+VE, PR+VE, HER2+VE, HIGH Ki67: (likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2)
• Group 3: - HER2 ENRICHED – 10-15%: ER-VE, PR-VE, HER2+VE: (likely to benefit from chemotherapy and treatment targeted to HER2)
• Group 4: - BASAL LIKE (TRIPLE NEGATIVE) 15-20%: ER-VE, PR-VE, HER2-VE: (No benefit from hormonal or anti HER2 but likely to benefit from selected chemotherapy)

NCCN Guidelines for the following:

A: Chemotherapy Regimens for Recurrent Metastatic Breast Cancer:

• Regimens for ER- and/or PR-Positive Recurrent or Stage IV (M1) Disease1, HER2-Negative and Postmenopausal or Premenopausal Receiving Ovarian Ablation or Suppression
• Regimens for ER- and/or PR-Positive Recurrent or Stage IV (M1) Disease1, HER2-Positive and Postmenopausal
• Regimens For Recurrent or Stage IV (M1) Disease1, HER2-Negative
• Regimens For Recurrent or Stage IV (M1) Disease1, HER2-Positive

B: Chemotherapy Regimens for Invasive Breast Cancer 

• Adjuvant Endocrine Therapy: Hormone Receptor-Positive Disease: Premenopausal at diagnosis / Postmenopausal at diagnosis
• Neoadjuvant/Adjuvant Chemotherapy, HER2-negative Disease / HER2-positive Disease

2. Cervical Cancer: Cervical Cancer

3. Urologic Cancers: Bladder, Prostate, Kidney Testes

4. Sarcoma: SOFT TISSUE SARCOMA TREATMENT REGIMENS